- ISIN
- US55234L1052
- CUSIP
- 55234L105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 1, 2020
Highlights
- EPS (TTM)
- -$21.14
- Total Revenue (TTM)
- $600.00K
- Gross Profit (TTM)
- $300.00K
- EBITDA (TTM)
- -$30.56M
- Year Range
- $0.31 - $27.42
- Target Price
- $0.50
- ROA (TTM)
- -91.25%
- ROE (TTM)
- 307.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LYRA Performance Chart
Lyra Therapeutics, Inc. (LYRA) is down 77.3% since the beginning of the year. At $1 per share, LYRA is trading 97.4% below its 52-week high of $27. Investors who bought $1,000 worth of LYRA shares 5 years ago would now be looking at an investment worth $2.
Loading charts...
Returns By Period
Lyra Therapeutics, Inc. (LYRA) has returned -77.27% so far this year and -97.46% over the past 12 months.
Lyra Therapeutics, Inc.
- 1D
- 0.00%
- 1M
- -6.67%
- YTD
- -77.27%
- 6M
- -83.29%
- 1Y
- -97.46%
- 3Y*
- -82.90%
- 5Y*
- -71.49%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
LYRA Monthly Returns History
Based on dividend-adjusted daily data since May 1, 2020, LYRA's average daily return is -0.10%, while the average monthly return is -4.30%.
Historically, 35% of months were positive and 65% were negative. The best month was Jun 2025 with a return of +81.7%, while the worst month was May 2024 at -93.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, LYRA closed higher 44% of trading days. The best single day was Jun 2, 2025 with a return of +310.8%, while the worst single day was May 6, 2024 at -87.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -42.21% | -43.26% | -51.38% | 43.56% | 4.96% | -5.41% | -77.27% | ||||||
| 2025 | -11.43% | 17.07% | -40.98% | -5.94% | -17.00% | 81.74% | -25.22% | 4.48% | -6.77% | -11.74% | -35.94% | -16.53% | -70.16% |
| 2024 | -13.17% | 15.60% | 18.25% | -17.04% | -93.64% | -15.64% | 17.60% | -1.14% | -20.11% | 6.96% | -24.70% | -0.29% | -96.06% |
| 2023 | -9.24% | -16.49% | -15.55% | 19.40% | 7.08% | 59.92% | -21.65% | 8.07% | 12.36% | -24.04% | 11.45% | 58.31% | 66.88% |
| 2022 | -6.19% | 19.07% | -17.45% | 40.55% | -5.31% | 5.61% | 14.87% | -10.79% | -13.47% | -6.39% | -25.16% | -10.54% | -27.98% |
| 2021 | -7.28% | 41.15% | -22.32% | -13.11% | -28.70% | 11.84% | -19.80% | 10.87% | 27.79% | -19.99% | -23.29% | -22.14% | -61.75% |
Benchmark Metrics
Lyra Therapeutics, Inc. has an annualized alpha of -29.20%, beta of 0.49, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 04, 2020.
- This stock participated in 189.94% of S&P 500 Index downside but only -113.73% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.49 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.20%
- Beta
- 0.49
- R²
- 0.00
- Upside Capture
- -113.73%
- Downside Capture
- 189.94%
Return for Risk
Risk / Return Rank
LYRA ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lyra Therapeutics, Inc. (LYRA) and compare them to S&P 500 Index.
| LYRA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.70 | 2.24 | -2.94 |
Sortino ratioReturn per unit of downside risk | -1.99 | 3.07 | -5.06 |
Omega ratioGain probability vs. loss probability | 0.71 | 1.41 | -0.70 |
Calmar ratioReturn relative to maximum drawdown | -0.98 | 2.93 | -3.91 |
Martin ratioReturn relative to average drawdown | -1.15 | 13.52 | -14.67 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lyra Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lyra Therapeutics, Inc. was 99.96%, occurring on Mar 23, 2026. The portfolio has not yet recovered.
The current Lyra Therapeutics, Inc. drawdown is 99.92%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.96%Mar 2026 | 5y 10mo | — | 6y 1moMay 2020 - now |
Drawdown Indicators
| LYRA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -56.78% | -43.18% |
Max Drawdown (1Y)Largest decline over 1 year | -98.42% | -9.10% | -89.32% |
Max Drawdown (3Y)Largest decline over 3 years | -99.88% | -18.90% | -80.98% |
Max Drawdown (5Y)Largest decline over 5 years | -99.91% | -25.43% | -74.48% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.92% | -0.74% | -99.18% |
Average DrawdownAverage peak-to-trough decline | -75.66% | -10.72% | -64.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 84.00% | 1.97% | +82.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lyra Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lyra Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LYRA relative to other companies in the Biotechnology industry. Currently, LYRA has a P/S ratio of 1.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LYRA
Add Lyra Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LYRA